Similar benefits were observed in transgenic 3xTg-AD mice, where these treatments reduced expression of pro-apoptotic and pro-inflammatory proteins, lowered levels of phosphorylated tau, and decreased amyloid-β plaque burden. The gene discussed is MAPT; the disease is Alzheimer disease.